“To patent or not to patent? the case of Novartis’ cancer drug Glivec in India”
نویسندگان
چکیده
منابع مشابه
“To patent or not to patent? the case of Novartis’ cancer drug Glivec in India”
BACKGROUND Glivec (imatinib mesylate), produced by the pharmaceutical company Novartis, is prescribed in the case of chronic myeloid leukemia, one of the most common blood cancers in eastern countries. After more than a decade of legal battles surrounding its patentability, the Supreme Court of India gave its final decision on April 1st of 2013, rejecting the appeal of the Swiss giant drug manu...
متن کاملTo patent or not to patent: the European Union's new biotech directive.
IV. PATENTABILITY OF BIOTECHNOLOGICAL INVENTIONS IN EUROPE............................................................................ 583 A. The European Patent Convention............................. 583 B. Directive 98/44/EC of the European Parliament and the Council of the European Union on the Legal Protection of Biotechnological Inventions ...... 589 1. Procedure for Adoption of a Directi...
متن کاملfrom linguistics to literature: a linguistic approach to the study of linguistic deviations in the turkish divan of shahriar
chapter i provides an overview of structural linguistics and touches upon the saussurean dichotomies with the final goal of exploring their relevance to the stylistic studies of literature. to provide evidence for the singificance of the study, chapter ii deals with the controversial issue of linguistics and literature, and presents opposing views which, at the same time, have been central to t...
15 صفحه اولPatent ductus arteriosus: to treat or not to treat?
Persistent patency of the ductus arteriosus in the preterm infant is associated with numerous morbidities, including higher rates of bronchopulmonary dysplasia and increased mortality. These strong associations have led to widespread use of cyclooxygenase inhibitors and surgical ligation to achieve ductal closure in the expectation that closing the ductus will reduce these complications. Each o...
متن کاملRewarding Incremental Innovation in Cancer Research
Volume 5(6) 1000e123 J Cancer Sci Ther ISSN:1948-5956 JCST, an open access journal The landmark decision to rejection of patent to anti-cancer drug ‘Glivec’ by Indian Supreme Court has catalysed range of debates around importance of innovation in research and development. The patent plea by Novartis for beta crystalline for of imanitib (i.e. glivec) was considered as an attempt to extend period...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Globalization and Health
سال: 2014
ISSN: 1744-8603
DOI: 10.1186/1744-8603-10-3